Analysis

Black Diamond Therapeutics, Inc. (BDTX) Stock Analysis

Black Diamond Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysis connected to BDTX.

websiteBDTX/analysis/BDTX

Black Diamond Therapeutics, Inc.

Black Diamond Therapeutics, Inc. investors can use 6ix to track stock price context, company news, investor events, webinar replays, and AI-assisted analysisconnected to BDTX.

Stock profile

Ticker

BDTX

Asset type

Stock

Market cap

$95.1M

Sector

Health Technology

Industry

Biotechnology

Currency

USD

Ticker listings

Black Diamond Therapeutics, Inc. may appear across multiple exchanges or ticker formats. 6ix consolidates those listings around the canonical analysis page for discovery.

  • BDTX primary listing

Latest Black Diamond Therapeutics, Inc. news

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical Mutations

Black Diamond Therapeutics Announces Positive Phase 2 Results for Silevertinib in Frontline NSCLC Patients with EGFR Non-Classical

Black Diamond Therapeutics to Host Webcast for Investors Highlighting Updated Results from Phase 2 Trial of Silevertinib in 1L EGFRm NSCLC

Webcast will be held Thursday, May 21, 2026, at 5:30 p.m. ET CAMBRIDGE, Mass., May 19, 2026 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage...

Black Diamond Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Oral presentation of silevertinib Phase 2 data in frontline EGFRm NSCLC patients, including preliminary DOR and PFS data, to take place at the 2026 ASCO Annual MeetingFirst pati...

Black Diamond Therapeutics Announces Oral Presentation of Silevertinib Phase 2 Data in Frontline EGFRm NSCLC Patients at the 2026 ASCO An...

Poster also to be presented on the Phase 2 data of silevertinib in recurrent EGFRm NSCLC patients Trial-in-progress poster to be presented on the randomized

Black Diamond Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update

Clinical update on track for Q2 2026 for Phase 2 trial of silevertinib in patients with non-classical EGFRm NSCLC, including preliminary DOR and PFS data in frontline settingCom...

Research sections

Valuation

Review valuation context for Black Diamond Therapeutics, Inc..

Future growth

Review future growth context for Black Diamond Therapeutics, Inc..

Past performance

Review past performance context for Black Diamond Therapeutics, Inc..

Financial health

Review financial health context for Black Diamond Therapeutics, Inc..

Dividend

Review dividend context for Black Diamond Therapeutics, Inc..

Management

Review management context for Black Diamond Therapeutics, Inc..

Ownership

Review ownership context for Black Diamond Therapeutics, Inc..

Other information

Review other information context for Black Diamond Therapeutics, Inc..

Community

Review community context for Black Diamond Therapeutics, Inc..